FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3213612154> ?p ?o ?g. }

• W3213612154 endingPage "804" @default.
• W3213612154 startingPage "804" @default.
• W3213612154 abstract "Abstract BACKGROUND: Current guidelines for AML ascribe disease-risk partly based on NPM1 and FLT3 mutational status. NPM1 mutations (mut) occur in 25%-30% of patients (pts) with AML and are associated with favorable prognosis in the absence of co-occurring FLT3-ITD. FLT3-ITD alterations are observed in ~15-30% of AML pts and confer poor prognosis, whereas the prognostic implication of FLT3-TKD point mutations (~7% of pts) is less clear. Post-IC, absence of MRD is associated with favorable relapse-free and overall survival (RFS/OS). In the randomized, phase 3 QUAZAR AML-001 trial, Oral-AZA (CC-486) significantly prolonged OS and RFS vs placebo (PBO) in older pts with AML in first remission after IC (Wei, NEJM 2020). It is of high interest to understand the effects of Oral-AZA in pts with NPM1 and/or FLT3 mutations, and whether their outcomes are influenced by post-IC MRD status. OBJECTIVE: Evaluate survival outcomes with Oral-AZA vs PBO in pts with NPM1mut ± FLT3mut at AML diagnosis (Dx), and OS by baseline (BL) MRD status (+/-) in pts with NPM1/FLT3 mutations. METHODS: In QUAZAR AML-001, pts aged ≥55 years with AML and NCCN intermediate or poor-risk cytogenetics at Dx were randomized 1:1 to receive Oral-AZA 300 mg or PBO QD within 4 mo after attaining first CR/CRi with IC (induction ± consolidation). NPM1 and FLT3 statuses (mut or wild-type [wt]) at AML Dx (before IC) were collected from pt diagnostic case report forms. MRD analyses were conducted by MFC (≥0.1% MRD+ cutoff) in bone marrow aspirate samples collected at screening (post-IC; ie, BL). OS and RFS were estimated from the time of randomization using Kaplan-Meier methods. Multivariate (MV) Cox regression analyses of the prognostic effects on OS/RFS were performed, with NPM1 and FLT3 mutational status and cytogenetic risk at Dx; post-IC MRD status (+/-) at BL, and randomized Tx (Oral AZA vs PBO) as variables. RESULTS: Of 472 pts enrolled , 469 (99.4%) had mutational data available at Dx, and the MRD-evaluable cohort comprised 463 pts (98.1%). In all, 137 pts (29%; Oral-AZA n = 66, PBO n = 71) had NPM1mut at AML Dx, and NPM1mut was significantly correlated with MRD- status at BL (post-IC)(P = 0.0178). Among pts with NPM1mut, OS was significantly improved in pts receiving Oral-AZA vs PBO, whether pts were MRD- (median 48.6 vs 26.2 mo, respectively) or MRD+ (median 39.4 vs 10.3 mo) at BL (both P &lt; 0.0001) (Figure). While median OS for NPM1mut pts in the Oral-AZA arm was nominally improved for MRD- pts vs. those MRD+ (48.6 vs. 39.4 mo, respectively), median OS for NPM1mut pts in the PBO arm was substantially influenced by post-IC MRD status (26.2 vs 10.3 mo for MRD- and MRD+ pts, respectively) (Figure). Similarly, median RFS for pts with NPM1mut/MRD- in the Oral-AZA and PBO arms was 24.9 vs 9.9 mo, respectively, and for pts with NPM1mut/MRD+ was 19.4 vs 4.6 mo. In all, 66 pts (14.1%) had FLT3-ITD (n = 46) and/or FLT3-TKD mut (n = 24) at AML Dx; NPM1 and FLT3-ITD status was NPM1mut + FLT3-ITD - in 107 pts, NPM1mut + FLT3-ITD + in 30 pts, and NPM1wt + FLT3-ITD + in 16 pts. In the Oral-AZA arm, median OS in pts with FLT3mut was not meaningfully different from that in pts with FLT3wt (28.2 and 24.7 mo, respectively), but FLT3mut conferred a negative prognosis in the PBO arm (median OS 9.7 mo, vs 15.2 mo for FLT3wt pts). Risk of death was reduced 46% with Oral-AZA vs PBO in pts with FLT3mut (HR 0.54 [95%CI 0.25, 1.14]). When considering MRD status, median OS in FLT3mut/MRD- pts was 28.2 vs. 15.9 mo in the Oral-AZA (n = 14) and PBO (n = 17) arms, respectively, and was 24.0 vs 8.0 mo in FLT3mut/MRD+ pts (Oral-AZA, n = 16; PBO, n = 18). In MV analyses, Oral-AZA significantly improved OS vs PBO when adjusted for other variables (P = 0.035); NPM1 status (P = 0.001), FLT3status (P = 0.035), and cytogenetic risk at Dx (P &lt; 0.001) were each also significantly predictive of OS, as was post-IC MRD status (P &lt; 0.001). All except FLT3 status (P = 0.737) were significantly predictive of RFS. CONCLUSIONS: Oral-AZA prolonged OS and RFS vs PBO in pts with NPM1mut, with improvements beyond the prognostic benefit conferred by MRD-, suggesting that pts with NPM1mut and MRD- can attain substantial OS benefit with Oral-AZA maintenance. An OS benefit was also observed with Oral-AZA vs PBO in pts in FLT3mut at Dx, but outcomes may be confounded by co-occurring NPM1mut, so further investigation is needed. MV analyses confirmed the independent prognostic influence of Oral-AZA, NPM1 and FLT3 mutations at Dx, cytogenetic risk at Dx, and post-IC MRD status on OS. Figure 1 Figure 1. Disclosures Döhner: Janssen: Honoraria; Helsinn: Honoraria; Gilead: Honoraria; GEMoaB: Honoraria; Celgene: Honoraria, Research Funding; Bristol Myers Squibb: Honoraria, Research Funding; Berlin-Chemie: Honoraria; AstraZeneca: Honoraria; Astex Pharmaceuticals: Honoraria; Astellas: Honoraria, Research Funding; Amgen: Honoraria, Research Funding; Agios: Honoraria, Research Funding; Jazz Pharmaceuticals: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Abbvie: Honoraria, Research Funding; Oxford Biomedica: Honoraria; Pfizer: Research Funding; Roche: Honoraria. Wei: Astellas: Honoraria; Novartis, Celgene, AbbVie, Servier, AstraZeneca, and Amgen: Research Funding; Novartis, Janssen, Amgen, Roche, Pfizer, Abbvie, Servier, BMS, Macrogenics, Agios, Gilead: Membership on an entity's Board of Directors or advisory committees. Roboz: Glaxo SmithKline: Consultancy; Helsinn: Consultancy; AbbVie: Consultancy; Jasper Therapeutics: Consultancy; Bayer: Consultancy; Novartis: Consultancy; Actinium: Consultancy; Agios: Consultancy; Blueprint Medicines: Consultancy; Astellas: Consultancy; AstraZeneca: Consultancy; Jazz: Consultancy; Daiichi Sankyo: Consultancy; Astex: Consultancy; Mesoblast: Consultancy; Amgen: Consultancy; MEI Pharma - IDMC Chair: Consultancy; Bristol Myers Squibb: Consultancy; Janssen: Consultancy; Otsuka: Consultancy; Celgene: Consultancy; Janssen: Research Funding; Pfizer: Consultancy; Roche/Genentech: Consultancy. Montesinos: Agios: Consultancy; Pfizer: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Daiichi Sankyo: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Sanofi: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Tolero Pharmaceutical: Consultancy; Incyte: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Forma Therapeutics: Consultancy; Glycomimetics: Consultancy; Teva: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Karyopharm: Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Astellas Pharma, Inc.: Consultancy, Honoraria, Other: Advisory board, Research Funding, Speakers Bureau; Stemline/Menarini: Consultancy. Thol: Abbvie: Honoraria; Astellas: Honoraria; BMS/Celgene: Honoraria, Research Funding; Jazz: Honoraria; Novartis: Honoraria; Pfizer: Honoraria. Ravandi: AstraZeneca: Honoraria; AbbVie: Honoraria, Research Funding; Agios: Honoraria, Research Funding; Jazz: Honoraria, Research Funding; Xencor: Honoraria, Research Funding; Syros Pharmaceuticals: Consultancy, Honoraria, Research Funding; Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Honoraria, Research Funding; Novartis: Honoraria; Astex: Honoraria, Research Funding; Prelude: Research Funding; Taiho: Honoraria, Research Funding. Dombret: Amgen: Honoraria, Research Funding; Incyte: Honoraria, Research Funding; Jazz Pharmaceuticals: Honoraria, Research Funding; Novartis: Research Funding; Pfizer: Honoraria, Research Funding; Servier: Research Funding; Abbvie: Honoraria; BMS-Celgene: Honoraria; Daiichi Sankyo: Honoraria. Sandhu: Celgene: Consultancy; Janssen: Consultancy; Takeda: Consultancy; Amgen: Consultancy; Bioverativ: Consultancy; Pfizer: Consultancy; Sanofi: Consultancy; Gilead: Consultancy. Skikne: Bristol Myers Squibb: Current Employment. See: Bristol Myers Squibb: Current Employment. Ugidos: Bristol Myers Squibb: Current Employment. Risueño: Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company, Patents & Royalties. Chan: Bristol Myers Squibb: Current Employment. Thakurta: Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company, Patents & Royalties. Beach: Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company. Lopes de Menezes: Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company, Patents & Royalties." @default.
• W3213612154 created "2021-11-22" @default.
• W3213612154 creator A5000436961 @default.
• W3213612154 creator A5000750846 @default.
• W3213612154 creator A5003682435 @default.
• W3213612154 creator A5005591514 @default.
• W3213612154 creator A5012863731 @default.
• W3213612154 creator A5015991333 @default.
• W3213612154 creator A5028526208 @default.
• W3213612154 creator A5029409714 @default.
• W3213612154 creator A5043776973 @default.
• W3213612154 creator A5043785211 @default.
• W3213612154 creator A5046911143 @default.
• W3213612154 creator A5050873337 @default.
• W3213612154 creator A5058195823 @default.
• W3213612154 creator A5067468389 @default.
• W3213612154 creator A5075305835 @default.
• W3213612154 creator A5076534799 @default.
• W3213612154 creator A5089395073 @default.
• W3213612154 date "2021-11-05" @default.
• W3213612154 modified "2023-10-12" @default.
• W3213612154 title "Prognostic Impact of <i>NPM1</i> and <i>FLT3</i> Mutations at Diagnosis and Presence of Measurable Residual Disease (MRD) after Intensive Chemotherapy (IC) for Patients with Acute Myeloid Leukemia (AML) in Remission: Outcomes from the QUAZAR AML-001 Trial of Oral Azacitidine (Oral-AZA) Maintenance" @default.
• W3213612154 doi "https://doi.org/10.1182/blood-2021-147465" @default.
• W3213612154 hasPublicationYear "2021" @default.
• W3213612154 type Work @default.
• W3213612154 sameAs 3213612154 @default.
• W3213612154 citedByCount "4" @default.
• W3213612154 countsByYear W32136121542022 @default.
• W3213612154 countsByYear W32136121542023 @default.
• W3213612154 crossrefType "journal-article" @default.
• W3213612154 hasAuthorship W3213612154A5000436961 @default.
• W3213612154 hasAuthorship W3213612154A5000750846 @default.
• W3213612154 hasAuthorship W3213612154A5003682435 @default.
• W3213612154 hasAuthorship W3213612154A5005591514 @default.
• W3213612154 hasAuthorship W3213612154A5012863731 @default.
• W3213612154 hasAuthorship W3213612154A5015991333 @default.
• W3213612154 hasAuthorship W3213612154A5028526208 @default.
• W3213612154 hasAuthorship W3213612154A5029409714 @default.
• W3213612154 hasAuthorship W3213612154A5043776973 @default.
• W3213612154 hasAuthorship W3213612154A5043785211 @default.
• W3213612154 hasAuthorship W3213612154A5046911143 @default.
• W3213612154 hasAuthorship W3213612154A5050873337 @default.
• W3213612154 hasAuthorship W3213612154A5058195823 @default.
• W3213612154 hasAuthorship W3213612154A5067468389 @default.
• W3213612154 hasAuthorship W3213612154A5075305835 @default.
• W3213612154 hasAuthorship W3213612154A5076534799 @default.
• W3213612154 hasAuthorship W3213612154A5089395073 @default.
• W3213612154 hasConcept C104317684 @default.
• W3213612154 hasConcept C11413529 @default.
• W3213612154 hasConcept C126322002 @default.
• W3213612154 hasConcept C143998085 @default.
• W3213612154 hasConcept C155512373 @default.
• W3213612154 hasConcept C2483381 @default.
• W3213612154 hasConcept C2776694085 @default.
• W3213612154 hasConcept C2778041864 @default.
• W3213612154 hasConcept C2778336483 @default.
• W3213612154 hasConcept C2778461978 @default.
• W3213612154 hasConcept C2778729363 @default.
• W3213612154 hasConcept C2779134260 @default.
• W3213612154 hasConcept C2779823535 @default.
• W3213612154 hasConcept C30481170 @default.
• W3213612154 hasConcept C41008148 @default.
• W3213612154 hasConcept C53226629 @default.
• W3213612154 hasConcept C54355233 @default.
• W3213612154 hasConcept C71924100 @default.
• W3213612154 hasConcept C86803240 @default.
• W3213612154 hasConceptScore W3213612154C104317684 @default.
• W3213612154 hasConceptScore W3213612154C11413529 @default.
• W3213612154 hasConceptScore W3213612154C126322002 @default.
• W3213612154 hasConceptScore W3213612154C143998085 @default.
• W3213612154 hasConceptScore W3213612154C155512373 @default.
• W3213612154 hasConceptScore W3213612154C2483381 @default.
• W3213612154 hasConceptScore W3213612154C2776694085 @default.
• W3213612154 hasConceptScore W3213612154C2778041864 @default.
• W3213612154 hasConceptScore W3213612154C2778336483 @default.
• W3213612154 hasConceptScore W3213612154C2778461978 @default.
• W3213612154 hasConceptScore W3213612154C2778729363 @default.
• W3213612154 hasConceptScore W3213612154C2779134260 @default.
• W3213612154 hasConceptScore W3213612154C2779823535 @default.
• W3213612154 hasConceptScore W3213612154C30481170 @default.
• W3213612154 hasConceptScore W3213612154C41008148 @default.
• W3213612154 hasConceptScore W3213612154C53226629 @default.
• W3213612154 hasConceptScore W3213612154C54355233 @default.
• W3213612154 hasConceptScore W3213612154C71924100 @default.
• W3213612154 hasConceptScore W3213612154C86803240 @default.
• W3213612154 hasIssue "Supplement 1" @default.
• W3213612154 hasLocation W32136121541 @default.
• W3213612154 hasOpenAccess W3213612154 @default.
• W3213612154 hasPrimaryLocation W32136121541 @default.
• W3213612154 hasRelatedWork W1970434092 @default.
• W3213612154 hasRelatedWork W2073730465 @default.
• W3213612154 hasRelatedWork W2081477164 @default.
• W3213612154 hasRelatedWork W2156781830 @default.
• W3213612154 hasRelatedWork W2186865501 @default.
• W3213612154 hasRelatedWork W2401840403 @default.
• W3213612154 hasRelatedWork W2979455368 @default.
• W3213612154 hasRelatedWork W3213612154 @default.
• W3213612154 hasRelatedWork W4319461823 @default.

• next